anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Coronary vasomotor dysfunction, an important underlying cause of angina and nonobstructive coronary arteries (ANOCA), encompassing coronary vasospasm, coronary endothelial dysfunction, and/or coronary microvascular dysfunction, is clinically assessed by invasive coronary function testing (ICFT). As ICFT imposes a high burden on patients and carries risks, developing noninvasive alternatives is important. We evaluated whether coronary vasomotor dysfunction is a component of systemic microvascular endothelial and smooth muscle dysfunction and can be detected using laser speckle contrast analysis (LASCA). Forty-three consecutive patients with ANOCA underwent ICFT, with intracoronary acetylcholine, adenosine, and flow measurements, to assess coronary vasomotor dysfunction. Cutaneous microvascular function was assessed using LASCA in the forearm, combined with vasodilators acetylcholine, sodium nitroprusside, and insulin and using EndoPAT, by measuring the reactive hyperemia index (RHI). Of the 43 included patients with ANOCA (79% women, 59 ± 9 yr old), 38 patients had coronary vasomotor dysfunction, including 28 with coronary vasospasm, 26 with coronary endothelial dysfunction, and 18 with coronary microvascular dysfunction, with overlapping endotypes. Patients with and without coronary vasomotor dysfunction had similar peripheral flow responses to acetylcholine, insulin, and RHI. In contrast, coronary vasomotor dysfunction was associated with lower peripheral flow responses to sodium nitroprusside (P < 0.001). An absolute flow response to sodium nitroprusside of 83.95 APU resulted in 86.1% sensitivity and 80.0% specificity for coronary vasomotor dysfunction (area under the ROC curve, 0.883; P = 0.006). In conclusion, this study provides evidence of systemic vascular smooth muscle dysfunction in patients with ANOCA with coronary vasomotor dysfunction and the diagnostic value of peripheral microvascular function testing as a noninvasive tool for detecting coronary vasomotor dysfunction.NEW & NOTEWORTHY This study provides proof of concept that assessment of the peripheral vasculature, particularly vascular smooth muscle cells measured using the LASCA technology holds potential as a noninvasive tool for detecting coronary vasomotor dysfunction. This finding highlights the potential of the LASCA technology in, for example, medication studies for coronary vasomotor dysfunction, especially when investigating whether medication improves vascular function, as repeated peripheral measurements are less invasive than invasive coronary function testing, the current gold standard.
The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called S. aureus is the most common cause of bone and joint infection. Methicillin resistant S. aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is increasingly common in U.S. and non-U.S. medical centers. Trauma-associated bone and joint infection is also a common problem. Victims of major trauma often suffer bone fractures, which require temporary or permanent use of metal or other synthetic devices such as external-fixation pins, plates, and screws. These synthetic devices can also get infected and cause bone and joint infections.

This problem will be studied by investigating whether an antibiotic called tedizolid is tolerable, safe and effective to treat bone and joint infections. Tedizolid is a new FDA-approved antibiotic, and can be given through the bloodstream via an IV or orally in the form of a pill. Tedizolid has less side effects compared to linezolid and is effective against types of bacteria like S. aureus. Other research also suggests that the side effects associated with long-term therapy of older types of antibiotics may not be found with tedizolid.

This study will advance scientific knowledge of antibiotic treatments for bone and joint infections. Given the large and increasing burden of disease of bone and joint infection and the increasing acceptability of oral antibiotics for its management, tedizolid holds promise as a good option for patients with bone and joint infection. Harbor-UCLA Medical Center is a large medical center in the County of Los Angeles, the most populous County in the United States. The Infectious Disease consult service sees many bone and joint infections. Use of prolonged antibiotics is common in this setting. The investigators believe tedizolid addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for bone and joint infection.
The structure of the N-substituted imidazole carboxylic ester compound with the ultrashort-effect anesthesia effect is shown as the formula . Wherein R is 、 Or is- (CH) 2 ) n OR ', wherein n = an integer of 1-3, R' is selected from C 1~4 And when n =2, R' is not methyl. The compound can produce a rapid and reversible general anesthesia effect. Animal experiments show that the compound and the pharmaceutically acceptable salt compound thereof have the characteristic of shorter effect than etomidate anesthetic effect, and suggest that the compound can be rapidly metabolized in vivo, can be used as a super-short-acting general anesthetic, is favorable for shortening the inhibition time of the compound on corticoids, and has obvious advantages and good application prospect. The compounds can be prepared by reacting N-substituted imidazole carboxylic acid compounds with the corresponding compoundsAlcohols, halogenated alcohols or esters, halides, etc. are obtained by condensation or substitution reactions.
PURPOSE: A fermentation of Bacillus subtilis-SKm is provided to improve the content of amino nitrogen and ammonium nitrogen by 10%-180% and to help fermentation. CONSTITUTION: Bacillus subtilis-SKm(KFCC 11520P) is isolated from meju(brick of dried fermented soybeans). The strain has one or more activities among protease activity, alpha-amylase activity, antioxidation activity, and cell growth suppression. The protease activity is 30 unit/g or greater. The alpha-amylase activity is 25 unit/g or greater. An anticancer agent contains a fermentation of the strain.
OBJECTIVES: I. Established the safety of VX-710 in combination with doxorubicin and vincristine for the treatment of patients with recurrent small cell lung cancer. II. Characterized the plasma pharmacokinetics of this regimen in patients. III. Established the ability of this regimen to improve the response rate to chemotherapy in patients who relapsed on front-line therapy. IV. Evaluated the multidrug resistance profile of these patients following this treatment regimen.

OUTLINE: This was a multicenter study. Stage I: Patients received VX-710 IV over 72 hours, followed by doxorubicin IV and vincristine IV four hours after initial VX-710. Vincristine was administered at half dose in the first 3-6 patients. If no more than 1 of 6 patients experienced a dose limiting toxicity in the half dose cohort, 3 additional patients received full dose vincristine. The maximum tolerated dose was defined as the dose preceding that at which 2 of 6 patients experienced a dose limiting toxicity. Stage II: Patients received VX-710 IV over 72 hours, followed by doxorubicin IV and full dose vincristine IV four hours after initial VX-710. Treatment continued for up to 6 courses every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients were followed every 3 months for up to 1 year.

PROJECTED ACCRUAL: A minimum of 35 and a maximum of 92 patients was to be accrued for this study.
PURPOSE:To provide a liquid drug for external use, having high solubility, excellent feeling to the skin and sufficiently high drug effect, and useful as a non- steroidal antiphlogistic and analgesic agent, by using indomethacin as an active component. CONSTITUTION:The objective drug can be prepared by dissolving indomethacin in a base consisting of a lower alcohol and/or acetone, crotamiton, and glycols (e.g. propylene glycol, butylene glycol, etc.) and/or their esters (e.g. polyethylene glycol monolaurate) by stirring. The amounts of lower alcohol and/or acetone, crotamiton, and glycols and/or their esters are preferably 50-90 V/V%, 0.5- 20 W/V%, and 5-50 W/V%, respectively. EFFECT:The addition of crotamiton to the base is effective to the prevention of the crystallization at the coating part of the vessel caused by the rapid evaporation of the solvent.
OBJECTIVES: Acinetobacter baumannii (A. baumannii) nosocomial infections represent a serious hazard to public health, given high mortality rates and rapid spread of multidrug-resistance. The primary outcome of this study was to evaluate predictors of 14- and 30-d mortality in bloodstream infections (BSIs) due to both carbapenem-resistant and carbapenem-sensitive Acinetobacter. Secondary end points were to identify risk factors for BSIs due to carbapenem-resistant A. baumannii (CRAB) and to develop a predictive model for mortality in CRAB-related BSIs.
METHODS: Between 2019 and 2023, all consecutive hospitalized adult patients with bacteraemia due to A. baumannii were retrospectively enrolled at a single-centre.
RESULTS: One hundred twenty-six episodes of BSI caused by A. baumannii were recorded, 89.7% of which were due to CRAB. Recent burn injuries, older age, previous CRAB colonization, and antibiotics exposure were identified as risk factors for acquiring CRAB BSI. Overall, 14-d mortality was observed in 26.1% of the patients and 30-d mortality in 30.9% of the patients. On multivariate analysis, the Sequential Organ Failure Assessment (SOFA) score was associated with both 14- and 30-d mortality, whereas burn injuries correlated with 30-d survival. Concurrent coronavirus disease (COVID) was associated with mortality, although not reaching statistical figures. No major impact of receiving appropriate treatment was observed. Based on these findings, a multivariable model to predict mortality among patients with CRAB BSI was built and internally validated.
CONCLUSIONS: A. baumannii BSIs are characterized by poor outcomes and limited therapeutic options. This study aimed to assist physicians in prompt identification of patients who are at greater risk of death, contributing to more informed clinical decision making.
BACKGROUND: TMC1 is one of the most common deafness genes causing DFNA36. Patient-derived human induced pluripotent stem cells (iPSCs) provide an opportunity to modelling diseases. TMC1 p.M418K mutation in human is orthologous to Beethoven mice. Here, we investigated the differentiation, morphology and electrophysiological properties of hair cell-like cells (HC-like cells) derived from DFNA36 patient.
METHODS: Inner ear HC-like cells were induced from iPSCs derived from DFNA36 (TMC1 p.M418K) patient (M+/-), normal control (M+/+) and genetic corrected iPSCs (M+/C). Immunofluorescence, scanning electron microscopy and whole-cell patch-clamp were used to study the mechanism and influence of TMC1 p.M418K mutation.
RESULTS: In this study we successfully generated HC-like cells from iPSCs with three different genotypes. HC-like cells from M+/- showed defected morphology of microvilli and physiological properties compared to M+/+. HC-like cells from M+/C showed recovery in morphology of microvilli and physiological properties.
CONCLUSIONS: Our results indicate that TMC1 p.M418K mutation didn't influence inner ear hair cell differentiation but the morphology of microvilli and electrophysiological properties and gene correction induced recovery. CRISPR/Cas9 gene therapy is feasible in human patient with TMC1 p.M418K mutation.
PURPOSE:To provide the titled preparation free of irritation and adhesion to the digestive tracts, having mild activity, and high absorption efficiency in blood, and exhibiting long effect by the administration of a small dose, by filling the gap between liposomes with an easily water-soluble acetylsalicylic acid salt. CONSTITUTION:Yolk lecithin is mixed with cholesterol and dipalmityl glycerophosphate, and the mixture is dissolved in chloroform, etc. and cast. Chloroform is evaporated from the cast film to obtain lipid film. The film is mixed with a phosphate buffer solution containing an easily water-soluble acetylsalicylic acid salt (e.g. acetylsalicylic acid DL-lysine salt of formula), and the dispersion is subjected to ultrasonic treatment to fill the gaps between the liposomes with the acetylsalicylic acid salt and to obtain the objective preparation.
Up to 25% of patients recovering from antibiotic-treated Clostridioides difficile infection (CDI) develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS). For patients with persistent symptoms following infection, a clinical dilemma arises as to whether to provide additional antibiotic treatment or to adopt a conservative symptom-based approach. Here, we review the literature on CDI-related PI-IBS and compare the findings with PI-IBS. We review proposed mechanisms, including the role of C. difficile toxins and the microbiota, and discuss implications for therapy. We suggest that gut dysfunction post-CDI may be initiated by toxin-induced damage to enteroglial cells and that a dysbiotic gut microbitota maintains the clinical phenotype over time, prompting consideration of microbiota-directed therapies. While Fecal Microbial Transplant (FMT) is currently reserved for recurrent CDI (rCDI), we propose that microbiota-directed therapies may have a role in primary CDI in order to avoid or mitigate futher antibiotic treatment that further disrupts the microbiota and thus prevent PI-IBS. We discuss novel microbial transfer therapies and as they emerge, we recommend clinical trials to determine whether microbial transfer therapy of the primary infection prevents both rCDI and CDI-related PI- IBS.
PURPOSE: A cosmetic composition for skin whitening obtained by blending an aqueous phase, in which a suitable amount of lecithin as an emulsifier is dispersed, with an oil phase which contains 5,15-diacetyl-3-benzoyllathyrol is provided. The composition is excellent in long-term storageability, skin safety and ease of use as well as enhanced transdermal absorption. CONSTITUTION: The nanoemulsion cosmetic composition for skin whitening comprises: an oil phase(A) containing 1 to 40% by weight of an oil phase component and 0.00001 to 10% by weight of 5,15-diacetyl-3-benzoyllathyrol; and an aqueous phase containing 0.5 to 10% by weight of lecithin. The cosmetic composition for skin whitening contains 1 to 50% by weight of a nanoemulsion cosmetic composition. The lecithin is hydrogenated lecithin obtained by hydrogenation of lecithin extracted from any one selected from the group consisting of egg yolk, soybeans, rape seeds, sunflowers, cotton seeds and corn seeds. he nanoemulsion has an average particle size of 250 to 350nm.
Patients 12years of age and above 

The startingdose is 300 mg three times a day. The recommended maintenance dose of gabapentin is 300 mg to 600 mg threetimes a day. Dosages up to 2400 mg/day have been well tolerated in long-termclinical studies. Doses of 3600 mg/day have also been administered to a smallnumber of patients for a relatively short duration, and have been welltolerated. Administer gabapentinthree times a day using 300 mg or 400 mg capsules. The maximum time betweendoses should not exceed 12 hours. 

PediatricPatients Age 3 to 11 years 

The starting dose range is 10 mg/kg/day to 15 mg/kg/day, given in threedivided doses, and the recommended maintenance dose reached by upward titrationover a period of approximately 3 days. The recommended maintenance dose of gabapentin in patients 3 to 4 years ofage is 40 mg/kg/day, given in three divided doses. The recommended maintenancedose of gabapentin in patients 5to 11 years of age is 25 mg/kg/day to 35 mg/kg/day, given in three divideddoses. Gabapentin may beadministered as the oral capsule. Dosages up to 50 mg/kg/day have been welltolerated in a long-term clinical study. The maximum time interval betweendoses should not exceed 12 hours.
School-based immunizations are fear-inducing events for many students and contribute to vaccine hesitancy. We developed an immunization delivery framework called the CARD (Comfort Ask Relax Distract) system that incorporates evidence-based interventions to improve the experience (eg, reduce fear, pain, dizziness). We evaluated CARD in grades 6 and 9 students in Calgary, Canada. In this pragmatic, hybrid, effectiveness-implementation, cluster trial, we randomized 8 Community Health Centres providing regional immunization services to CARD or control (usual care). In the CARD group, public health staff educated students about CARD and planned processes to reduce fear cues and support student coping choices during immunization. Students self-reported fear, pain, and dizziness during immunization using a 0-10 numerical rating scale; staff recorded procedure details, including vaccines administered, fainting episodes, and coping strategies used. Staff participated in focus groups afterward. Altogether, 8839 children from 105 schools in the 2019 to 2020 school calendar year were included. Fear was lower for CARD (mean = 3.6 [SD = 3.1] vs control 4.1 [3.2]; mean difference = -0.5; 95% confidence interval = -0.74 to -0.21; P < 0.001). Effectiveness persisted after stratification by student gender (male and female) and grade level (grade 6 and grade 9). Other symptoms did not differ. Compared with control, CARD students used peers, privacy, muscle tension, and topical anesthetics more; verbal distraction, deep breathing, and adult support were used less frequently ( P < 0.05, all analyses). Immunization rate did not differ. Staff reported positive to neutral attitudes about CARD. In summary, this pragmatic trial demonstrated that CARD improved the immunization experiences of students at school.
PURPOSE: Achieving a secure anastomosis and complete hemostasis is essential for surgically treating type A acute aortic dissection (TAAAD). This study assessed the clinical feasibility of "tailored stand-up collar (TSC)" technique for constructing the distal stump.
METHODS: We enrolled 68 patients who underwent ascending aortic repair for TAAAD. Patients were categorized according to the technique for distal stump construction: conventional (C) group using only a felt strip (32 cases); post-aortotomy (P) group, with a Hydrofit-felt strip attached after aortotomy (18 cases), and TSC group, where a Hydrofit-felt strip attached during cooling (18 cases). Pre-operative characteristics, procedural profiles, and post-operative outcomes were evaluated.
RESULTS: The pre-operative characteristics were identical among the groups. The durations of cardiopulmonary bypass, hemostasis, and surgery were significantly shorter in the P and TSC groups. The duration of open distal in the TSC group (21 min) was significantly shorter than the other two groups. Post-operative additional procedures were not required for the TSC group and their post-operative hospital stay was significantly shorter (47.1% of patients were discharged within 2 weeks).
CONCLUSION: The TSC technique would be practical because of its high reproducibility in terms of ease of use, shorter anastomotic time, and secure hemostasis.
Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Entrepreneurs will participate in a 3 day residential training (based on SEE Change's Empowered Entrepreneur training) that integrates personal agency with basic business and leadership topics. Participants will also get weekly support messages on their phone for 6 weeks and a check in by a training once a month for 3 months.
PURPOSE: To prepare a medicine for treating illnesses of respiratory organs containing chenodeoxycholic acid. CONSTITUTION: This medicine comprises one of bile acid, chenodeoxycholic acid as an active ingredient. Also one of bile acid, ursodeoxycholic acid can be contained as an active ingredient to provide a therapeutic agent for illnesses of respiratory organs. Otherwise, the chenodeoxycholic acid and the ursodeoxycholic acid in combination are contained. The resultant therapeutic agent is useful for acute and chronic inflammatory illnesses, especially upper respiratory tract system, e.g. chronic bronchitis, chronic pharyngitis, chronic tonsillitis, etc. The chemical formula of the chenodeoxycholic acid is 3α,7α- dihydroxy-(3α,5β,7α)-cholan-24-oic acid and the compositional formula thereof is C24 H40 O4 . The chemical formula of the ursodeoxycholic acid is 3α,7α- dihydroxy-(3α,5β,7β)-cholan-24-oic acid.
The invention relates to the technical field of tumor medicine, in particular to a ligand conjugate and a probe for combining PMSA, and a preparation method and application thereof. The invention discloses a ligand conjugate for binding PMSA. The ligand conjugate can be specifically combined with PSMA, has targeting property, and can be used for treating, imaging and diagnosing prostate tumor. In addition, the ligand conjugate contains polyethylene glycol high polymer which has good water solubility. According to experimental data, the ligand conjugate has high water solubility and good stability when being used as a magnetic probe for targeting prostate cancer. The combination of mouse in vivo experiment test results shows that the kit has the characteristics of good imaging performance and strong targeting performance, has high affinity to PSMA, and is beneficial to early diagnosis of prostate cancer.